article thumbnail

Promising schizophrenia drug faces tough competition

European Pharmaceutical Review

LY03010 was well tolerated and showed no unexpected treatment-emergent adverse events (TEAEs) compared to Invega Sustenna ®. Should LY03010 receive US Food and Drug Administration (FDA) approval, Luye Pharma will need to provide solid marketing and competitive pricing to set it apart from competitors and convince payers to reimburse it.”.

article thumbnail

Capture Videos of HCPs at Events!

Storyvine

Your branded Storyvine video is ready in minutes, so you can post while you’re still at the event. Get a jump on the competition. We make it easy to capture videos of doctors talking about your brand, which you can use on your website, social media accounts, and other marketing materials.

Doctors 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

An Inside Look at Penrod’s Annual Event: The Penrodpalooza

Penrod

And true to our nature, our people followed through with gallant resolve (read: we’re competitive af). The post An Inside Look at Penrod’s Annual Event: The Penrodpalooza appeared first on Penrod. One of the categories was “I can’t believe we all fit in here!” Palooza is the perfect summary of this ideology. Apply here !

Food 52
article thumbnail

How Essentials Research Supported Established Brand with Agile Syndicated Tracking

InCrowd

A well-known, established blockbuster brand at a top-10 pharma company needed a better solution for tracking its highly competitive market. Their traditional, data-heavy, time-consuming, and expensive ATU wasn’t meeting their needs. Get the case study today!

article thumbnail

ESMO 2022: Ten key takeaways on Europe’s top oncology event

Clarivate

As part of the Drugs to Watch program, Clarivate experts use proprietary data sources, landscape and event monitoring and deep market knowledge to identify key drug developments expected to have a significant impact on patients and markets. Fruquintinib will face fierce competition should it be approved in the third- and later-line setting.

article thumbnail

Novel heart failure drug could halt disease progression

European Pharmaceutical Review

Study findings acoramidis was found to reduce the number of patients who were hospitalised due to a heart-related event” Compared with placebo, acoramidis was found to reduce the number of patients who were hospitalised due to a heart-related event. The drug was also shown to lower cardiac congestion.

article thumbnail

Navigating research challenges through collaboration and Equity

Clarivate

Deciphering the trends in research funding Staying up to date is made easier by following reports and events that examine the ebb and flow of research funding and provide insights into the priorities and strategies of major funding organizations. Institutions that do not form international collaborations risk disenfranchisement.